Enjoy complimentary customisation on priority with our Enterprise License!
The nontuberculous mycobacterial infections market size is forecast to increase by USD 4.33 billion, at a CAGR of 5.66% between 2023 and 2028.
Explore in-depth regional segment analysis with market size data - historical 2018-2022 and forecasts 2024-2028 - in the full report.
Request Free Sample
Nontuberculous mycobacterial (NTM) infections continue to pose a significant challenge in the healthcare industry due to their diverse clinical presentations and increasing incidence. These infections, which can manifest in various forms such as in water, extrapulmonary, disseminated, mycobacterium kansasii, and others, are characterized by their ability to thrive in various environments and affect multiple organ systems. Mycobacterium kansasii, for instance, is a common cause of pulmonary NTM infections, while Mycobacterium avium complex is often associated with disseminated infections. NTM infections have been reported in various sectors, including travelers, HIV patients, infants, and the elderly, among others.
The ongoing research in NTM infection management, diagnosis, and prevention is crucial in addressing the evolving patterns of these infections. For instance, advancements in NTM infection diagnosis have led to the development of more accurate and rapid diagnostic tools, while research into NTM infection microbiology and pathogenesis continues to provide insights into the underlying mechanisms of these infections. NTM infections can also occur in various body sites, including the urine, blood, joint, ear, and tissue, among others. Furthermore, NTM infections have been linked to various environmental sources, such as water, soil, and bioaerosols, highlighting the importance of infection control and prevention measures.
The dynamic nature of NTM infections necessitates continuous monitoring and surveillance, particularly in high-risk populations. As such, awareness and education efforts are essential in preventing the spread of these infections and improving patient outcomes. In conclusion, the NTM infection landscape is characterized by its complexity and diversity, requiring a multifaceted approach to address the ongoing challenges in diagnosis, management, and prevention. The continuous unfolding of market activities and evolving patterns in NTM infections underscore the importance of ongoing research and innovation in this field.
The nontuberculous mycobacterial infections industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
.
The hospital pharmacies segment is estimated to witness significant growth during the forecast period.
Nontuberculous Mycobacterial (NTM) infections are a significant challenge in healthcare settings, affecting various body systems and patient populations, including water, extrapulmonary, and disseminated infections caused by mycobacteria such as mycobacterium kansasii, mycobacterium xenopi, mycobacterium avium complex, mycobacterium fortuitum, and mycobacterium abscessus. Hospital pharmacies play a vital role in managing NTM infections by ensuring the availability of essential medications for diagnosis, treatment, and prevention. These medications include amikacin, ethambutol, and macrolides. Hospital pharmacies collaborate closely with suppliers and pharmaceutical companies to procure these drugs, which are then stored in the pharmacy inventory. Inventory management systems help maintain adequate stock levels, ensuring timely access to these medications.
NTM infection research is ongoing to improve diagnosis, treatment, and prevention strategies, including the development of new drugs and diagnostic tools. NTM infections can affect various patient populations, including travelers, HIV patients, infants, elderly individuals, and those with underlying conditions like diabetes or cancer. Infections can occur in various body sites, such as the urinary tract, bloodstream, joints, lungs, skin, and ear. NTM infections can also form biofilms, making treatment challenging. Early diagnosis and prompt treatment are crucial for managing NTM infections. Microbiological testing, such as culture and molecular methods, is used for diagnosis. Infection control measures, including proper Hand Hygiene, environmental cleaning, and isolation precautions, help prevent NTM infections in healthcare settings.
NTM infections can have severe consequences if left untreated, leading to long-term complications and increased healthcare costs. Therefore, awareness and prevention efforts are essential. This includes education of healthcare professionals and the public, as well as surveillance and outbreak response. In summary, hospital pharmacies serve as critical intermediaries in the distribution of NTM infection-related medications, collaborating with suppliers and pharmaceutical companies to ensure their availability. Effective inventory management and documentation of patient data are essential for optimal patient care. Ongoing research and prevention efforts aim to improve diagnosis, treatment, and prevention strategies for NTM infections.
The Hospital pharmacies segment was valued at USD 4.97 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Nontuberculous Mycobacterial (NTM) infections represent a growing health concern in North America, particularly among individuals with underlying respiratory conditions or compromised immune systems. These infections, which can manifest in various forms such as pulmonary, extrapulmonary, disseminated, or localized, are caused by several Mycobacterium species, including Mycobacterium kansasii, Mycobacterium xenopi, Mycobacterium avium complex, Mycobacterium fortuitum, Mycobacterium chelonae, and Mycobacterium abscessus, among others. NTM infections can occur in various body sites, including water, urine, blood, joints, skin, and the respiratory system. NTM infections in water have been linked to outbreaks in public swimming pools and hot tubs.
Travelers are also at risk of contracting NTM infections while visiting countries with high endemicity. Researchers are actively studying the microbiology, diagnosis, and treatment of NTM infections to improve patient outcomes. NTM infections in HIV-positive individuals and infants are of particular concern due to their weakened immune systems. NTM infections can form biofilms, making them difficult to eradicate, and can cause chronic diseases such as bronchiectasis and chronic obstructive pulmonary disease (COPD). According to the Centers for Disease Control and Prevention (CDC), approximately 16 million Americans suffer from COPD, with millions more undiagnosed and untreated worldwide.
NTM infections in the respiratory system can lead to severe lung damage and disability. Early diagnosis and prevention are crucial in managing NTM infections. Awareness campaigns and education initiatives are essential to increase public understanding of NTM infections and their risk factors. NTM infection control measures include proper water disinfection, hand hygiene, and infection prevention practices in healthcare settings. NTM infections can also occur in animals, bone, elderly individuals, and various other body sites, highlighting the need for continued research and surveillance. In conclusion, the NTM infection market is driven by the increasing prevalence of NTM infections, particularly in individuals with underlying respiratory conditions or compromised immune systems.
Growing awareness and research efforts are contributing to earlier diagnosis and treatment, fueling market growth. Continued education and prevention initiatives are essential to mitigate the risks and complications associated with NTM infections.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The nontuberculous mycobacterial infections market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the nontuberculous mycobacterial infections market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, nontuberculous mycobacterial infections market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Abbott Laboratories - This organization specializes in the development and provision of innovative pharmaceutical solutions.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Dive into Technavio's robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Nontuberculous Mycobacterial Infections Market insights. See full methodology.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
177 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.66% |
|
Market growth 2024-2028 |
USD 4.33 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
5.25 |
|
Key countries |
US, UK, Germany, Japan, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
We can help! Our analysts can customize this nontuberculous mycobacterial infections market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
